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Background:  Hyponatremia (serum sodium [Na]≤135mmol/L) is a predictor of morbidity and mortality in patients with heart failure (HF), but the 
long term outcomes associated with hyponatremia are less clear. We aimed to evaluate the long-term outcomes of hyponatremic patients in a large 
HF cohort.
Methods:  This is an observational study using the Duke Databank for Cardiovascular Disease. Patients from Duke Medical Center undergoing 
cardiac catheterization from Jan 2000 - Dec 2008, with a diagnosis of HF (NYHA class II-IV) due to systolic dysfunction (LVEF<40%), were included. 
Serum sodium measurement at the time of catheterization was used to assess sodium status. Baseline characteristics and outcomes for patients 
with hyponatremia were compared to those without hyponatremia. Kaplan-Meier survival estimates were generated out to 6 years, with a median 
follow-up time of 3.8 years in the study population.
Results:  1047 patients were enrolled. For the entire cohort median age was 61; 70% were male; median EF was 27%. 16% of the patients had 
hyponatremia. The hyponatremic group had significantly worse survival at 6 years (p=.0001). (Figure).
Conclusion: Hyponatremia was associated with worse survival for HF patients in our cohort. Hyponatremia is an important risk factor for poor 
outcomes and a potential target for the development of new therapies. 
